TP53 and prostate carcinoma: Treatment with ReACp53 rescued p53 function in aggregation-prone mutant p53-bearing human ovarian and prostate cancer cells, leading to inhibition of cell proliferation in vitro and tumor shrinkage in vivo14,42.